Evotec
Sanja Jelin-Ferizovic is a seasoned professional in construction and infrastructure management, currently serving as Global Sr. Manager of Construction and Infrastructure at Evotec since March 2023. Previously, Sanja held the position of Director of Facility Management at CENTOGENE from September 2019 to March 2023, along with experience as Head of Facility Maintenance at CENTOGENE AG in Rostock, Germany. Prior roles include significant contributions at the Clinical Center University of Sarajevo, where Sanja worked from March 2005 to September 2019 in various capacities, including Expert Associate Engineer and Director of the Technical Sector. Additionally, Sanja has experience in international relations through a role with the Commission to Preserve National Monuments in Bosnia and Herzegovina and held internships at IFC SEED World Bank and iMed Italy. An architect by training, Sanja holds a Master's degree from the University of Sarajevo and a Master's degree from the European University Centre for Cultural Heritage in Italy.
This person is not in any teams
This person is not in any offices
Evotec
5 followers
Evotec AG is a drug discovery and development company. The Company operates through two segments. The EVT Execute segment provides standalone drug discover services on a typical fee-for-service basis or integrated drug discovery collaborations on partners' target through a range of commercial structures, including research fees, milestones and/or royalties. The EVT Innovate segment develops drug discovery programs and assets, both internally or through academic collaborations. The Company seeks to partner these into collaborations in return for upfront payments, ongoing research payments. It consists of all partnerships derived from its internally developed assets and platforms and its participations in certain companies. It includes clinical initiations and progress of clinical pipeline within partnerships; expansion of academic BRIDGE network; research and development (R&D) progress with CureX/Target X initiatives, and focuses on induced pluripotent stem cells (iPSC) platform.